» Articles » PMID: 23316341

Cancer Treatment Using Peptides: Current Therapies and Future Prospects

Overview
Journal J Amino Acids
Date 2013 Jan 15
PMID 23316341
Citations 163
Authors
Affiliations
Soon will be listed here.
Abstract

This paper discusses the role of peptides in cancer therapy with special emphasis on peptide drugs which are already approved and those in clinical trials. The potential of peptides in cancer treatment is evident from a variety of different strategies that are available to address the progression of tumor growth and propagation of the disease. Use of peptides that can directly target cancer cells without affecting normal cells (targeted therapy) is evolving as an alternate strategy to conventional chemotherapy. Peptide can be utilized directly as a cytotoxic agent through various mechanisms or can act as a carrier of cytotoxic agents and radioisotopes by specifically targeting cancer cells. Peptide-based hormonal therapy has been extensively studied and utilized for the treatment of breast and prostate cancers. Tremendous amount of clinical data is currently available attesting to the efficiency of peptide-based cancer vaccines. Combination therapy is emerging as an important strategy to achieve synergistic effects in fighting cancer as a single method alone may not be efficient enough to yield positive results. Combining immunotherapy with conventional therapies such as radiation and chemotherapy or combining an anticancer peptide with a nonpeptidic cytotoxic drug is an example of this emerging field.

Citing Articles

Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model.

Nguyen C, Vu T, Nguyen M, Tran-Nguyen T, Huynh C, Ha Q Cancer Immunol Immunother. 2025; 74(4):145.

PMID: 40072566 DOI: 10.1007/s00262-025-03992-7.


Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal Adenocarcinoma.

Winning A, Sietsema W, Buck K, Linsmeier A, Wiczling P Clin Pharmacol Drug Dev. 2025; 14(3):240-251.

PMID: 39789733 PMC: 11905876. DOI: 10.1002/cpdd.1502.


Lam. Leaf Peptides: Antioxidant and Antiproliferative Activity in Human Colon Cancer Caco-2 Cell Line.

Aviles-Gaxiola S, Contreras-Angulo L, Garcia-Aguiar I, Heredia J Antioxidants (Basel). 2024; 13(11).

PMID: 39594509 PMC: 11590870. DOI: 10.3390/antiox13111367.


Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment.

Sood A, Jothiswaran V, Singh A, Sharma A Explor Target Antitumor Ther. 2024; 5(5):1074-1099.

PMID: 39351437 PMC: 11438574. DOI: 10.37349/etat.2024.00264.


Polypeptides-Based Nanocarriers in Tumor Therapy.

You J, Guo Y, Dong Z Pharmaceutics. 2024; 16(9).

PMID: 39339228 PMC: 11435007. DOI: 10.3390/pharmaceutics16091192.


References
1.
Park K, Kim Y, Lee G, Park R, Kim I, Kim S . Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res. 2008; 25(12):2786-98. DOI: 10.1007/s11095-008-9643-y. View

2.
Smolarczyk R, Cichon T, Graja K, Hucz J, Sochanik A, Szala S . Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta Biochim Pol. 2006; 53(4):801-5. View

3.
Walensky L, Kung A, Escher I, Malia T, Barbuto S, Wright R . Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004; 305(5689):1466-70. PMC: 1360987. DOI: 10.1126/science.1099191. View

4.
Senter P, Sievers E . The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30(7):631-7. DOI: 10.1038/nbt.2289. View

5.
Grunnet M, Sorensen J . Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2011; 76(2):138-43. DOI: 10.1016/j.lungcan.2011.11.012. View